Patient-derived 3D Tumour Organoid Models
Recent advances in the establishment of primary patient-derived tumour cell cultures hold great promise not only to improve our understanding of tumour biology, but also to significantly enhance the identification of truly individualised cancer therapies.
This is why we have partnered with cpo cellular phenomics & oncology GmbH, a company that has meanwhile sourced and cultured more than 200 different patient-derived 3D tumour cell models.
Together with cpo, we provide our clients with integrated compound testing services using PD3D® cell models.
Our joint offerings:
Please email us to learn more about our services.
Compound testing services by cpo
Back-up of phenotypic data by cpo's NGS-based genomic profiles
Generation of comprehensive proteomic and phospho-proteomic signatures (e.g., pre- vs post-treatment) via DigiWest or RPPA